Table 4. Multivariate analysis of overall survival according to nodal status.
Node negative (n = 81) | Node positive (n = 37) | |||
Variables | Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
Age | ||||
≥60 vs. <60 years | 2.26 (0.89–5.70) | 0.085** | 5.25 (1.68–16.36) | 0.004* |
Gender | ||||
Male vs. Female | 0.21 (0.05–0.81) | 0.024* | 0.74 (0.15–3.65) | 0.713 |
Site | ||||
Oral cavity vs. Non-oral cavity | 0.93 (0.29–2.96) | 0.898 | 2.39 (0.40–14.28) | 0.339 |
T | ||||
T3/T4 vs. T1/T2 | 3.70 (1.43–9.58) | 0.007* | 2.17 (0.69–6.86) | 0.186 |
(Neo)Adjuvant treatment | ||||
Any vs. None | 1.14 (0.46–2.86) | 0.774 | 1.54 (0.27–8.74) | 0.625 |
pAMPK | ||||
Positive vs. negative | 0.45 (0.19–1.08) | 0.072** | 0.67 (0.23–1.97 ) | 0.472 |
pACC | ||||
High expression vs. negative or low expression | 1.55 (0.61–3.88) | 0.355 | 17.58 (3.50–88.18) | <0.001* |
pErk | ||||
Positive vs. negative | 0.49 (0.15–1.58) | 0.232 | 0.41 (0.11–1.53) | 0.184 |
*P<0.05; **P<0.1.
T, tumor; pAMPK, phosphorylated AMP-activated protein kinase; pACC, phosphorylated acetyl-CoA carboxylase; pErK, phosphorylated extracellular signal-regulated kinase; n, patient number; HR, hazard ratio; 95% CI, 95% confidence interval.